***Commonwealth of Massachusetts***

***Executive Office of Health and Human Services***

***Office of Medicaid***

[*www.mass.gov/masshealth*](http://www.mass.gov/masshealth)

MassHealth

# All Provider Bulletin 349

# August 2022

**TO**: All Providers Participating in MassHealth

**FROM**: Amanda Cassel Kraft, Assistant Secretary for MassHealth [signature of Amanda Cassel Kraft]

RE: Coverage and Reimbursement Policy for Bebtelovimab

## Background

This bulletin provides information around future pricing of bebtelovimab, a monoclonal antibody used for the treatment of Coronavirus Disease 2019 (COVID-19).

This bulletin applies to members enrolled in MassHealth fee-for-service, the Primary Care Clinician (PCC) Plan, Primary Care ACOs (PCACOs), and MassHealth Limited. MassHealth Accountable Care Partnership Plans (ACPPs), managed care organizations, Senior Care Organizations (SCOs), One Care plans, and Programs of All-inclusive Care for the Elderly (PACE) must provide plan-covered services to enrollees in an amount, duration, and scope that is no more restrictive than MassHealth fee-for-service coverage for such services, including as set forth in this bulletin.

## Billing for Bebtelovimab

EOHHS previously added coverage for bebtelovimab, a monoclonal antibody used for the treatment of COVID-19, using code Q0222 SL with a price of zero because it was supplied by the federal government at no cost to providers. EOHHS understands that federal supplies may not be available in the future and that providers will need to begin purchasing the product. For supplies that are not free, EOHHS intends to pay eligible providers (other than pharmacies) at the same rate as Medicare, using code Q0222, as described in the table that follows. Pharmacies will be reimbursed for bebtelovimab consistent with 101 CMR 331: Prescribed Drugs.

For free supplies, providers should continue billing Q0222 SL. EOHHS will formally establish the rate for this code through administrative bulletins or amendments to relevant pricing regulations, and MassHealth will issue transmittal letters that formally add this code to the relevant provider manuals.

| **Code** | **Description** | **Rate** | **Effective Date** |
| --- | --- | --- | --- |
| Q0222 | Injection, bebtelovimab, 175 mg | $2394.00 | 08/15/2022 |

## MassHealth Website

This bulletin is available on the [MassHealth Provider Bulletins](http://www.mass.gov/masshealth-provider-bulletins) web page.

[Sign up](https://www.mass.gov/forms/email-notifications-for-masshealth-provider-bulletins-and-transmittal-letters) to receive email alerts when MassHealth issues new bulletins and transmittal letters.

## Questions

### Dental Services

Phone: (800) 207-5019; TTY: (800) 466-7566

### Long-Term Services and Supports

Phone: (844) 368-5184 (toll free)

Email: [support@masshealthltss.com](mailto:support@masshealthltss.com)

Portal: MassHealthLTSS.com

Mail: MassHealth LTSS

PO Box 159108

Boston, MA 02215

Fax: (888) 832-3006

### All Other Provider Types

Phone: (800) 841-2900. TDD/TTY: 711.

Email: [providersupport@mahealth.net](file:///C:\Users\THoitink\Downloads\providersupport@mahealth.net)

Fax: (617) 988-8974

Follow us on Twitter [***@MassHealth***](https://twitter.com/masshealth).